Supplementary Documents [IFRS]

Financial results for the first three months of the fiscal year 2026 (FY2026)

Astellas Pharma Inc.

- Q1 YTD/FY2026 Financial Results
- Pipeline list

<u>*Cautionary Notes*</u>

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[Three months ended June 30, 2026]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year	Forecasts FY26 Full Year	Change from FY25 Change (%)
Revenue	505.8	640.9	135.1	26.7%	2,139.2	2,220.0	3.8%
Cost of sales	94.8	122.7	27.9	29.4%	408.4	445.0	9.0%
Gross profit	411.0	518.2	107.2	26.1%	1,730.8	1,775.0	2.6%
SG&A expenses	197.0	215.1	18.1	9.2%	860.3	800.0	-7.0%
XTANDI co-promotion fee in the United States	62.9	67.5	4.6	7.2%	248.2	216.0	-13.0%
SG&A excl. the above	134.1	147.6	13.5	10.1%	612.1	584.0	-4.6%
Ratio to Revenue	26.5%	23.0%			28.6%	26.3%	
R&D expenses	71.7	81.7	10.0	14.0%	314.8	355.0	12.8%
Ratio to Revenue	14.2%	12.8%			14.7%	16.0%	
Amortisation of intangible assets	32.8	35.7	2.9	8.9%	136.0		
Gain on divestiture of intangible assets	3.7	-	-3.7	-	4.3		
Share of profit (loss) of investments accounted for using equity method	-1.6	-0.8	0.7	-	-1.8		
Other income	4.4	3.9	-0.5	-10.4%	32.8		
Net foreign exchange gains	-	3.2	3.2	-	4.9		
Fair value remeasurements on contingent consideration	4.0	-	-4.0	-	16.9		
Other expenses	21.3	4.3	-17.0	-79.8%	72.4		
Impairment losses for intangible assets	13.6	0.0	-13.5	-99.6%	52.8		
Restructuring costs	2.8	1.9	-0.9	-33.6%	9.9		
Net foreign exchange losses	2.3	-	-2.3	-	-		
Operating profit	94.6	184.5	89.9	94.9%	382.6	395.0	3.2%
Ratio to Revenue	18.7%	28.8%			17.9%	17.8%	
Finance income	1.7	5.1	3.5	207.8%	8.0		
Finance expenses	5.9	3.1	-2.8	-47.1%	14.1		
Profit before tax	90.4	186.5	96.1	106.3%	376.6	385.0	2.2%
Income tax expense	22.0	44.8	22.8	103.5%	85.0		
Profit	68.4	141.8	73.3	107.2%	291.6	300.0	2.9%
Comprehensive income	34.9	183.6	148.7	426.2%	449.5		

2. Consolidated Results (Core Basis)

Unit: B¥

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year	Forecasts FY26 Full Year	Change from FY25 Change (%)
Revenue	505.8	640.9	135.1	26.7%	2,139.2	2,220.0	3.8%
Cost of sales	94.8	122.7	27.9	29.4%	408.4	445.0	9.0%
Gross profit	411.0	518.2	107.2	26.1%	1,730.8	1,775.0	2.6%
SG&A expenses	197.0	215.1	18.1	9.2%	860.3	800.0	-7.0%
XTANDI co-promotion fee in the United States	62.9	67.5	4.6	7.2%	248.2	216.0	-13.0%
SG&A excl. the above	134.1	147.6	13.5	10.1%	612.1	584.0	-4.6%
Ratio to Revenue	26.5%	23.0%			28.6%	26.3%	
R&D expenses	71.7	81.7	10.0	14.0%	314.8	355.0	12.8%
Ratio to Revenue	14.2%	12.8%			14.7%	16.0%	
Operating profit	142.3	221.4	79.1	55.6%	555.7	620.0	11.6%
Ratio to Revenue	28.1%	34.5%			26.0%	27.9%	
Finance income	1.7	5.1	3.5	207.8%	8.0		
Finance expenses	5.9	3.1	-2.8	-47.1%	14.1		
Profit before tax	138.0	223.4	85.4	61.9%	549.6		
Income tax expense	33.3	53.0	19.6	58.9%	125.2		
Profit	104.7	170.5	65.8	62.8%	424.4	460.0	8.4%

3. Exchange Rate

Unit: ¥

	FY25 APR. - JUN.Ave.	FY26 APR. - JUN.Ave.	FY25 End	FY26 Q1 End	FY25 Full Year	Forecasts FY26 Full Year
USD/Yen	145	159	159	163	151	150
EUR/Yen	164	185	183	186	175	180

* Fx impacts: Revenue +60.0 billion yen and Core operating profit +25.5 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY25 APR. - JUN.			FY26 APR. - JUN.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	**505.8**	**-**	**505.8**	**640.9**	**-**	**640.9**
Cost of sales	94.8	-	94.8	122.7	-	122.7
Gross profit	**411.0**	**-**	**411.0**	**518.2**	**-**	**518.2**
SG&A expenses	197.0	-	197.0	215.1	-	215.1
R&D expenses	71.7	-	71.7	81.7	-	81.7
Amortisation of intangible assets *	32.8	-32.8	-	35.7	-35.7	-
Gain on divestiture of intangible assets *	3.7	-3.7	-	-	-	-
Share of profit (loss) of investments accounted for using equity method *	-1.6	1.6	-	-0.8	0.8	-
Other income *	4.4	-4.4	-	3.9	-3.9	-
Other expenses *	21.3	-21.3	-	4.3	-4.3	-
Operating profit	**94.6**	**47.6**	**142.3**	**184.5**	**36.9**	**221.4**
Finance income	1.7	-	1.7	5.1	-	5.1
Finance expenses	5.9	-	5.9	3.1	-	3.1
Profit before tax	**90.4**	**47.6**	**138.0**	**186.5**	**36.9**	**223.4**
Income tax expense	22.0	11.3	33.3	44.8	8.2	53.0
Profit	**68.4**	**36.3**	**104.7**	**141.8**	**28.7**	**170.5**

* 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets', 'Share of profit (loss) of investments accounted for using equity method', 'Other income' and 'Other expenses' are excluded from Core basis results.
"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

		FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year	Forecasts FY26 Full Year	Change from FY25 Change (%)
Revenue		505.8	640.9	135.1	26.7%	2,139.2	2,220.0	3.8%
	United States	224.7	288.8	64.1	28.5%	940.2		
	Ratio to Revenue	44.4%	45.1%			44.0%		
	Japan	68.9	79.6	10.7	15.5%	289.0		
	Ratio to Revenue	13.6%	12.4%			13.5%		
	Established Markets	128.8	152.2	23.4	18.2%	563.6		
	Ratio to Revenue	25.5%	23.7%			26.3%		
	China	29.4	32.1	2.6	8.9%	101.5		
	Ratio to Revenue	5.8%	5.0%			4.7%		
	International Markets	53.2	85.4	32.2	60.5%	230.7		
	Ratio to Revenue	10.5%	13.3%			10.8%		

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

6. Investment in Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year	Forecasts FY26 Full Year	Change from FY25 Change (%)
Investment in Property, Plant and Equipment	4.8	10.1	5.2	108.2%	49.3	55.0	11.5%
Depreciation (PP&E)	11.1	11.1	-0.1	-0.5%	43.6	45.0	3.1%
Amortisation of Intangible Assets (incl. software, etc.)	36.7	38.8	2.1	5.8%	151.0	155.0	2.7%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

7. Sales of major products

1) Global

Unit: B¥

		FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year	Forecasts FY26 Full Year	Change from FY25 Change (%)
Strategic Brands Total		112.0	160.3	48.3	43.2%	480.3	610.0	27.0%
PADCEV		55.5	75.5	20.0	36.0%	221.2		
	United States	31.7	45.4	13.7	43.2%	129.2		
	Japan	5.1	4.9	-0.2	-4.1%	20.3		
	Established Markets	9.5	17.5	8.0	84.4%	52.2		
	China	7.4	4.1	-3.3	-45.1%	9.8		
	International Markets	1.8	3.6	1.8	100.6%	9.6		
IZERVAY		15.9	27.2	11.2	70.3%	77.6		
	United States	15.9	27.0	11.1	69.3%	77.5		
	Japan	-	0.1	0.1	-	0.1		
VYLOY		14.0	21.1	7.1	50.7%	63.1		
	United States	5.9	9.9	4.0	68.5%	29.9		
	Japan	3.1	3.5	0.4	13.7%	13.7		
	Established Markets	1.7	3.4	1.7	104.0%	11.3		
	China	3.3	3.6	0.3	9.8%	6.7		
	International Markets	0.1	0.8	0.6	502.0%	1.5		
VEOZAH		9.6	14.9	5.3	54.8%	46.6		
	United States	8.6	12.5	3.9	45.8%	40.6		
	Established Markets	0.9	1.9	1.0	107.2%	4.8		
	International Markets	0.1	0.5	0.4	254.1%	1.1		
XOSPATA		17.0	21.6	4.6	27.3%	71.8		
	United States	7.4	9.6	2.2	30.0%	32.0		
	Japan	1.3	1.5	0.2	11.5%	5.0		
	Established Markets	5.6	6.5	0.9	16.1%	23.0		
	China	1.0	1.5	0.5	49.3%	4.6		
	International Markets	1.7	2.6	0.9	51.3%	7.2		
XTANDI		233.0	276.6	43.6	18.7%	960.8	910.0	-5.3%
	United States	122.6	131.7	9.1	7.4%	483.7		
	Japan	15.9	18.9	3.0	18.9%	64.8		
	Established Markets	69.5	76.4	7.0	10.1%	291.0		
	China	4.8	7.1	2.3	47.1%	24.7		
	International Markets	20.2	42.5	22.3	110.4%	96.5		
BETANIS/MYRBETRIQ/BETMIGA		43.0	63.4	20.4	47.5%	189.7	180.0	-5.1%
PROGRAF		51.2	58.5	7.3	14.2%	207.7		

- Established Markets: Europe, Canada, etc.
- China: China, Hong Kong
- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.
- PADCEV (United States): Co-promotion revenue from Pfizer
- VEOZAH: Approved as “VEOZA” in ex-US

2) Revenue by Region

(1) United States

Unit: M$

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year
Revenue	1,555	1,812	257	16.5%	6,236
PADCEV	219	285	65	29.9%	857
IZERVAY	110	169	59	53.5%	514
VYLOY	41	62	21	52.8%	198
VEOZAH	59	79	19	32.2%	269
XOSPATA	51	60	9	17.9%	212
XTANDI	848	826	-22	-2.6%	3,209
MYRBETRIQ	107	201	94	88.4%	480
CRESEMBA	80	108	28	34.5%	362

(2) Japan

Unit: B¥

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year
Revenue	68.9	79.6	10.7	15.5%	289.0
PADCEV	5.1	4.9	-0.2	-4.1%	20.3
IZERVAY	-	0.1	0.1	-	0.1
VYLOY	3.1	3.5	0.4	13.7%	13.7
XOSPATA	1.3	1.5	0.2	11.5%	5.0
XTANDI	15.9	18.9	3.0	18.9%	64.8
EVENITY	16.5	23.2	6.7	40.3%	74.2

(3) Established Markets

Unit: M€

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)	FY25 Full Year
Revenue	786	821	36	4.5%	3,224
PADCEV	58	95	37	63.2%	299
VYLOY	10	18	8	80.5%	64
VEOZA	5	10	5	83.3%	27
XOSPATA	34	35	1	2.7%	132
XTANDI	424	413	-11	-2.6%	1,665

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)		FY25 Full Year
Revenue	29.4	32.1	2.6	8.9%		101.5
PADCEV	7.4	4.1	-3.3	-45.1%		9.8
VYLOY	3.3	3.6	0.3	9.8%		6.7
XOSPATA	1.0	1.5	0.5	49.3%		4.6
XTANDI	4.8	7.1	2.3	47.1%		24.7

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY25 APR. - JUN.	FY26 APR. - JUN.	Change	Change (%)		FY25 Full Year
Revenue	53.2	85.4	32.2	60.5%		230.7
PADCEV	1.8	3.6	1.8	100.6%		9.6
VYLOY	0.1	0.8	0.6	502.0%		1.5
VEOZA	0.1	0.5	0.4	254.1%		1.1
XOSPATA	1.7	2.6	0.9	51.3%		7.2
XTANDI	20.2	42.5	22.3	110.4%		96.5

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

8. Consolidated statements of financial position

Unit: B¥

	FY25 End	FY26 Q1 End	Change
Assets	**3,567.0**	**3,692.5**	**125.5**
Non-current assets	**2,145.1**	**2,206.9**	**61.8**
Property, plant and equipment	358.4	363.6	5.2
Goodwill	441.2	450.5	9.3
Intangible assets	996.9	1,022.7	25.8
Investments accounted for using equity method	20.3	20.5	0.2
Deferred tax assets	146.6	146.3	-0.3
Other financial assets	138.3	156.0	17.7
Other non-current assets	43.4	47.4	4.0
Current assets	**1,421.9**	**1,485.6**	**63.7**
Inventories	331.0	337.9	6.9
Trade and other receivables	746.8	831.7	84.9
Income tax receivable	15.0	13.1	-1.9
Other financial assets	9.6	11.2	1.6
Other current assets	38.0	47.0	9.1
Cash and cash equivalents	281.6	244.7	-36.9

Unit: B¥

	FY25 End	FY26 Q1 End	Change
Equity and Liabilities	**3,567.0**	**3,692.5**	**125.5**
Equity	**1,830.9**	**1,944.4**	**113.6**
Equity attributable to owners of the parent	**1,829.0**	**1,942.7**	**113.6**
Share capital	103.0	103.0	-
Capital surplus	185.2	181.7	-3.5
Treasury shares	-34.9	-31.7	3.3
Retained earnings	902.8	976.7	73.9
Other components of equity	673.0	713.0	40.0
Non-controlling interest	**1.8**	**1.8**	**-0.1**
Liabilities	**1,736.2**	**1,748.1**	**11.9**
Non-current liabilities	**517.8**	**513.3**	**-4.4**
Bonds and borrowings	320.0	320.0	-
Income tax payable	6.7	8.1	1.4
Deferred tax liabilities	1.3	3.0	1.8
Retirement benefit liabilities	21.5	21.6	0.1
Provisions	8.2	11.7	3.5
Other financial liabilities	89.1	89.2	0.2
Other non-current liabilities	71.0	59.7	-11.3
Current liabilities	**1,218.4**	**1,234.8**	**16.4**
Bonds and borrowings	246.0	269.9	23.9
Trade and other payables	199.8	192.3	-7.5
Income tax payable	68.9	43.4	-25.5
Provisions	23.5	22.9	-0.7
Refund liabilities	422.6	448.3	25.8
Other financial liabilities	22.3	29.8	7.4
Other current liabilities	235.3	228.2	-7.1

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China. As of Jul 2026

Underlined items indicate changes from the previous announcement in Apr 2026.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Cisplatin-ineligible muscle-invasive bladder cancer (combo with pembrolizumab)	Japan Filed (Jan 2026) Europe Approved (Jun 2026) China Filed (Jul 2026) NCT03924895	In-house [Co-development with Pfizer]	
			Cisplatin-eligible muscle-invasive bladder cancer (combo with pembrolizumab)	Europe Filed (Mar 2026) Japan Filed (May 2026) China Filed (Jul 2026) US Approved (Jul 2026) NCT04700124		
			Bladder-sparing muscle-invasive bladder cancer (combo with pembrolizumab)	P-III NCT07566156		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III NCT04027309	In-house	
			Post-chemotherapy maintenance acute myeloid leukemia	P-III		
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II NCT05520567		
			Acute myeloid leukemia in pediatric patients	P-III NCT04293562		
			ALK-positive non-small cell lung cancer	P-I NCT07140016		
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III NCT06901531	In-house (Ganymed)	

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
fezolinetant **ESN364** **(VEOZAH***)**	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III NCT06812754 Japan P-III NCT06206408 NCT06206421	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III NCT06440967		
avacincaptad pegol **(IZERVAY)**	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	China Filed (May 2026)	In-house (Iveric Bio)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.
*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Apr 2026):
enfortumab vedotin: Approved in Europe in Jun 2026 for cisplatin-ineligible muscle-invasive bladder cancer. Filed in Japan in May 2026 for cisplatin-eligible muscle-invasive bladder cancer. Filed in China in Jul 2026 for muscle-invasive bladder cancer. Approved in US in Jul 2026 for cisplatin-eligible muscle-invasive bladder cancer. Entered into Phase 3 for bladder-sparing muscle-invasive bladder cancer.
avacincaptad pegol: Filed in China in May 2026 for geographic atrophy secondary to age-related macular degeneration.

Programs with Focus Area approach

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
Immuno-oncology	**ASP2138**	T-cell engager	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I NCT05365581 NCT07024615	Xencor [Discovered through collaborative research]	
	ASP1002	T-cell engager	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I NCT05719558	In-house	
	VIR-5500	T-cell engager	Anti-PSMA and anti-CD3 T-cell engager	Prostate cancer	P-I NCT05997615	Vir Biotechnology	
	ASP2998	Antibody-drug conjugate (ADC)	TROP2 targeted dual-payload iADC	Cancer	P-I NCT07287995	Sutro Biopharma [Discovered through collaborative research]	
Induced Proximity	**setidegrasib**	Small molecule	KRAS G12D degrader	Pancreatic ductal adenocarcinoma	P-III NCT07409272	In-house	
				Cancer	P-I NCT05382559		
	ASP5834	Small molecule	Pan-KRAS degrader	Cancer	P-I NCT07094204	In-house	
Genetic regulation	**zocaglusagene nuzaparvovec AT845**	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-II NCT04174105	In-house (Audentes Therapeutics)	
	ASP2957	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-I NCT07052929	Kate Therapeutics/ Novartis	
Blindness and Regeneration	**ASP7317**	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I NCT03178149	In-house (Ocata Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
mirabegron **YM178**	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III NCT05621616	In-house	
roxadustat **ASP1517/FG-4592**	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III NCT05970172	Kyntra Bio	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate **ASP5541/PRL-02**	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-II NCT07005154	In-house (Propella Therapeutics)	
ASP546C/XNW27011	Antibody-drug conjugate (ADC)	Claudin 18.2-targeted ADC	Cancer	P-I NCT07488676	Evopoint Biosciences	Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and Taiwan.

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Rx+ Program

As of Jul 2026

Category	Program	Concept	Status*	Partner	Remarks
Digital health	**BlueStar**	Digital therapeutic for the management of diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
Drug-device combination	**pudexacianinium chloride ASP5354**	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
Implantable medical device	**Akyva**	Implantable device for underactive bladder	Early feasibility study	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.